Molecular imaging in Parkinson's disease by Cristina Polito
premio firenze university press
tesi di dottorato
– 18 – 
Collana Premio Tesi di doTToraTo 
Commissione giudicatrice, anno 2010
luigi lotti, Facoltà di Scienze Politiche (Presidente della Commissione)
Fortunato Tito arecchi, Facoltà di Scienze MFN 
Vincenzo Collotti, Facoltà di Lettere e Filosofia 
Paolo Felli, Facoltà di Architettura 
ada Fonzi, Facoltà di Psicologia 
Pelio Fronzaroli, Facoltà di Lettere e Filosofia 
roberto Genesio, Facoltà di Ingegneria 
Ferrando mantovani, Facoltà di Giurisprudenza 
mario Pio marzocchi, Facoltà di Farmacia 
salvo mastellone, Facoltà di Scienze della Formazione
adolfo Pazzagli, Facoltà di Medicina e Chirurgia 
Giancarlo Pepeu, Facoltà di Medicina e Chirurgia 
Franco scaramuzzi, Facoltà di Agraria
Piero Tani, Facoltà di Economia 
Fiorenzo Cesare Ugolini, Facoltà di Agraria
Cristina Polito




Immagine di copertina: © Luk Cox | Dreamstime.com
© 2011 Firenze University Press






Molecular imaging in Parkinson’s disease / Cristina 
Polito. – Firenze : Firenze University Press, 2011.
(Premio FUP. Tesi di dottorato ; 18)
http://digital.casalini.it/978866550419
ISBN  978-88-6655-037-2  (print)
ISBN  978-88-6655-041-9  (online)
Chapter 1 
Introduction 1
1.  Parkinson’s disease 1
2.  Molecular imaging in PD 3
2.1 Dopaminergic imaging 4
2.2  Non-dopaminergic imaging and extrastriatal systems 8
2.3  Brain metabolic imaging 9
3.  Molecular imaging biomarkers in PD 11
3.1  Dopaminergic imaging 11
3.2  Non-dopaminergic imaging 13





1.  Subjects 19
2.  Clinical and neuropsychological assessment 19
3.  MRI 20
4.  [123I]FP-CIT SPECT 20
5.  [18F]-FDG PET 20
6.  Statistical Parametric Mapping (SPM) 20
Chapter 4 
Study 1 Cerebral brain metabolism in drug-naïve Parkinson’s disease patients 23
1.  Background 23
2.  Methods 23 
2.1  Subjects 23
2.2  Statistical analysis 24
2.3  SPM 24
3.  Results 25
3.1  Demographic and clinical findings 25
3.2 SPM results 25
Contents
Cristina Polito, Molecular imaging in Parkinson’s disease ISBN  978-88-6655-037-2  (print) 
ISBN  978-88-6655-041-9  (online) © 2011 Firenze University Press
VI Cristina Polito
Chapter 5 
Study 2 Brain metabolic correlates of dopaminergic degeneration in de 
novo idiopathic Parkinson’s disease 29
1.  Background 29
2.  Methods 30
2.1  Subjects 30
2.2  Image analysis 30
2.3 SPM 31
3.  Results 31
Chapter 6 
Study 3 Functional changes related to dopamine depletion in the caudate 
nucleus in early Parkinson’s disease 35
1.  Background 35
2.  Methods 36
2.1  Subjects 36
2.2  Image analysis 38
2.3  Statistical analysis 38
2.4  SPM 38
3.  Results 39
3.1  [123I]FP-CIT SPECT and neuropsychological findings 39
3.2  Correlation with rCMRglc 40
Chapter 7 
Discussion 45
1.  Brain metabolism in drug naïve PD patients 45
2.  Early functional changes related to dopamine depletion in drug naïve 
PD patients 46
2.1  [123I]FP-CIT SPECT and clinical findings 46






Chapter 1  
Introduction 
 
1. Parkinson’s disease 
Parkinson's disease (PD) is a progressive neurodegenerative disorder, characte-
rized by asymmetric onset of resting tremor, rigidity, and bradykinesia followed by 
postural instability. The disease usually manifests during the sixth decade and the 
prevalence rates increase with age. European population-based studies suggest that 
the overall prevalence of PD in people aged over 65 is 1.8%, with an increase from 
0.6% for persons aged 65 to 69 years to 2.6% for people aged 85 to 89 years (de Rijk 
et al., 1995, 2000).The incidence of the disease rises steeply with age, from 17.4 in 
100000 person years between 50 and 59 years of age to 93.1 in 100000 person years 
between 70 and 79 years, with a lifetime risk of developing the disease of 1.5% 
(Bower et al., 1999). The median age of onset is 60 years and the mean duration of 
the disease from diagnosis to death is 15 years, with a mortality ratio of 2 to 1.5 
(Katzenschlager et al., 2008). 
The pathological hallmark of PD is a region-specific selective loss of dopami-
nergic, neuromelanin-containing neurons from the pars compacta of the substantia 
nigra, which results in striatal dopamine deficiency. This in turn leads to increased 
inhibitory output activity from the basal ganglia to the ventral thalamus and frontal 
cortex and subsequent development of parkinsonism (Bezard et al., 2003; Obeso et 
al., 2008). It has been estimated that, at the time of the first motor signs of PD at least 
30% of all the nerve cells in the pars compacta have already disappeared and, within 
5 years of diagnosis, 50% of the neurons will have died with an annual attrition rate 
of 7% of surviving neurons per year. Extrapolation of the rate of nigral cell loss back 
beyond the date of diagnosis suggests that neuronal damage could begin at least 5–10 
years before the first motor symptoms emerge (Fearnley and Lees, 1991). Cell loss in 
the locus coeruleus, dorsal nuclei of the vagus, raphe nuclei, nucleus basalis of Mey-
nert, and some other catecholaminergic brain stem structures including the ventro-
tegmental area also occur (Damier et al., 1999). Besides nerve-cell loss, three distinc-
tive intraneuronal inclusions can be found in PD: the Lewy body, the pale body, and 
the Lewy neurites. Synuclein immunocytochemistry studies reveal that intraneuronal 
Lewy body inclusions can be detected in the lower brainstem ahead of midbrain and 
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nigral involvement and later spread to limbic and association cortical areas in a pre-
dictable manner (Braak et al., 2003).  
PD usually occurs as a sporadic disorder, nevertheless few environmental factors 
have been identified (Dick et al., 2007). Aging is the major risk factor for PD, as for 
other neurodegenerative diseases (Lees et al., 2009). The protective role of tobacco 
against PD risk is still debated (Allam, 2004; Hernàn, 2001), as also the increased 
risk for PD in men and postmenopausal women not taking hormone replacement, 
who take no or low dose of caffeine (Ascherio et al., 2003, 2004). Weak associations 
between Parkinson‘s disease and head injury, rural living, middle-age obesity, lack of 
exercise, well-water ingestion, and herbicide and insecticide exposure have also been 
reported (Elbaz et al., 2007, Thaker et l., 2008). 
Genetic studies in PD identified over the past decade more than 13 loci and 9 
genes, but their implication in PD is still under investigation. Alpha-synuclein point 
mutations, duplications and triplications cause a rare dominant form of PD in familial 
and sporadic cases. Autosomal dominant PD is mainly caused by mutations in the 
leucine-rich repeat kinase 2 (LRRK2) gene particularly in certain ethnic groups. 
Loss-of-function mutations in Parkin, PINK1, DJ-1 and ATP13A2 cause autosomal 
recessive parkinsonism with early-onset (Lesage et al., 2009). 
The onset of PD motor symptoms is gradual and the early symptoms might be 
unnoticed and misinterpreted for a long time. The early clinical signs are often as-
cribed to old age or rheumatism, so that a lag of 2-3 years from first symptoms to di-
agnosis is not unusual. Early diagnosis of PD is desirable since in the very early stag-
es the neural damage is presumed to be more restricted. Therefore the principal aim 
of PD research in the last years has been to extend diagnosis to even earlier in the 
disease course (Marek and Jennings, 2009). 
Clinical, neuroimaging, and pathologic studies identified a variety of non motor 
symptoms which can precede the classic motor features of PD by years and, perhaps, 
even decades (Gonera et al., 1997; Abbot et al., 2003; Iranzo et al., 2006; Ross et al., 
2006 et al.; Haehner, 2007). Currently, the period when these symptoms arise is 
commonly referred to as the premotor phase of the disease (Tolosa et al., 2009) (Fig-
ure 1.1). A prenigral involvement at the basis of non motor symptoms, preceding 
classic motor PD features, is supported by Braak et al.(Braak et al., 2003) recent pro-
posal that synuclein pathology (Lewy bodies and neurites) in PD starts in the lower 
brainstem and progresses following a predictable caudal-rostral pattern, only reach-
ing the substantia nigra in the mesencephalon after extensive involvement of the 





Figure 1.1 Natural history of PD (from Marek, 2009). 
Among early non motor features of PD olfactory deficits and cardiac sympathetic 
denervation have been identified in a high proportion of patients at the time of the 
earliest motor signs, therefore suggesting that such features probably precede the mo-
tor signs. Other features documented in a smaller proportion of patients early in the 
course of the disease include pain, orthostatic hypotension, urinary urgency, and ex-
ecutive dysfunction found on neuropsychological testing (Lim et al., 2009). 
PD is therefore characterized by insidious onset and inexorable progression, so 
that growing interest is directed to the identification of reliable and well-validated 
biomarkers to identify individuals ―at risk‖ for PD, to accurately diagnose individuals 
at the threshold of clinical PD, and to monitor PD progression throughout its course 
(Marek and Jennings, 2009). In this perspective molecular imaging plays a key role. 
2. Molecular imaging in PD 
Molecular imaging refers to the use of non-invasive imaging techniques to detect 
signals that originate from molecules and their interaction with a specific cellular tar-
get in vivo. There are many different areas of investigation in the field of molecular 
imaging. Much research on neurodegenerative disorder is currently focused on de-
tecting pre-disease state or molecular states that occur before typical symptoms of a 
disease are clinically manifest (Herschman, 2003). 
PET and SPECT have been extensively employed to elucidate the functional 
changes associated with PD and other neurodegenerative parkinsonian disorders. 
Both modalities provide a means of assessing: (1) disease severity as reflected by 
presynaptic dopamine terminal dysfunction, (2) subclinical dysfunction in subjects 
who are at risk for PD, (3) disease progression and the effects on this of putative neu-
roprotective agents, and (4) changes in non-dopaminergic neurotransmission (Pavese 
et al., 2009). 
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2.1 Dopaminergic imaging 
Numerous PET and SPECT studies have investigated the nigrostriatal dopami-
nergic degeneration in PD patients (Booij et al., 1999; Brooks et al., 1997). Both pre- 
and post-synaptic dopaminergic functions can be measured (Figure 1.2). 
 
 
Figure 1.2. PET and SPECT radiopharmaceuticals in PD (from Thobois, 2001) 
Pre-synaptic aspects are mostly studied with [18F]-Fluoro-Dopa ([18F]-
FDOPA), a substrate for Dopa-decarboxylase in catecholaminergic neurons. [18F]-
FDOPA striatal uptake rate is correlated to cellular density of substantia nigra dopa-
minergic neurons and to striatal dopamine concentrations (Snow et al., 1993). Trac-
ers of dopamine pre-synaptic reuptake sites (dopamine transporter or DAT sites) 
were developed more recently. The first to be used was [11C]Nomifensine, a tracer 
for catecholamine uptake sites, largely replaced in recent years by the more selective 
tropanes as [123I]-b-carbomethoxy-3ß-(4-iodophenyl)- tropane ([123I]-β-CIT) and 
[123I-N-ω-fluoropropyl-2-β-carboxymethoxy-3β- (4-iodophenyl)nortropane] 
([123I]-FP-β-CIT), that are cocaine analogs. Post-synaptic receptor density is ex-
plored with dopamine receptor ligands, notably of the D2 type, as [11C]Raclopride 






Figure 1.3.Imaging dopamine terminal function in healthy controls and early Parkinson's dis-
ease (from Pavese, 2009). 
PRESYNAPTIC DOPAMINERGIC IMAGING 
 
The assessment of functional integrity of presynaptic nigrostriatal projections is 
one of the main applications of molecular imaging techniques in PD. Three different 
markers of presynaptic dopaminergic terminals are usually employed. 
 
Markers of striatal aromatic amino acid decarboxilase activity 
 
[18F]-FDOPA radiotracer uptake reflects the dopaminergic nerve density but at 
the same time, the activity of the aromatic amino acid decarboxylase enzyme 
(AADC) that converts dopa into dopamine and the storage of dopamine (Firnau et 
al., 1987). This radiotracer allows the study of the integrity of the presynaptic dopa-
minergic system in the nigrostriatal and also the mesolimbic and mesocortical dopa-
minergic pathways. 
The density of the axonal terminal plexus and the AADC activity is estimated by 
the uptake of [18F]-FDOPA in the striatal nuclei, measured by an influx constant Ki 
over 90 minutes. [18F]-FDOPA uptake in the striatum of patients with PD is influ-
enced by the number of remaining dopaminergic cells. Pathological studies, indeed, 
demonstrated that levels of striatal [18F]-FDOPA uptake correlated with nigral cell 
counts in PD experimental models (Snow et al., 1993; Pate et al., 1993). In the early 
stages, however, because of the presence of compensatory up-regulation of AADC 
[18F]-FDOPA PET may underestimate the degenerative process (Ribeiro et al., 
2002). 
Correlations have been found between [18F]-FDOPA putaminal uptake and clin-
ical severity of rigidity and bradykinesia as measured by the Unified Parkinson‘s 
Disease Rating Scale (UPDRS). Tremor severity was instead demonstrated not to be 
related with [18F]-FDOPA uptake, suggesting that either non-nigrostraital and/or 
non-dopaminergic pathways are involved in the pathogenesis of this symptom 
(Brooks et al., 1990; Vingerhoets et al., 1997; Broussolle et al., 1999). 
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[18F]-FDOPA uptake reduction seems to follow a gradient along the rostro-
caudal axis of the striatum. In patients with hemiparkinsonism dorsal posterior puta-
men is characterized by the greatest reduction in [18F]-FDOPA uptake. As the dis-
ease progress to bilateral parkinsonism, the ventral and anterior putamen and the dor-
sal caudate show additional reductions, and finally in the advanced stages reductions 
extends to the ventral head of the caudate (Morrish et al., 1995). [18F]-FDOPA find-
ings are in line with post mortem studies reporting an uneven pattern of dopamine 
loss in PD striatum. Dopaminergic cell loss occur first in the ventrolateral subregions 
of SNpc, which projects to dorsal putamen (Kish et al., 1988). 
The annual decrement in the [18F]-FDOPA influx has been estimated to be of 
9% to 13% in putamen and 3% in caudate nucleus (Morrish et al., 1998; Nurmi et al., 
2000). These data suggest that the degeneration of dopaminergic neurons is an active 
process during both the preclinical period and the symptomatic phase of disease. 
Increased [18F]-FDOPA uptake has been reported in early PD in dorsolateral 
prefrontal cortex, anterior cingulate and globus pallidus pars interna. Increased extra-
striatal [18F]-FDOPA uptake in early PD is presumably due to compensatory up-
regulation of AACD (Rakshi et al., 1999; Kaasinen et al., 2001; Whone et al., 2003). 
 
Markers of presynaptic dopamine transporter binding 
 
The presynaptic dopamine transporter (DAT), a plasma membrane transporter 
with high affinity for dopamine, is uniquely found in dopaminergic dendrites and 
axons; it is therefore a potential marker of nigrostriatal projections integrity. DAT 
availability is commonly measured by several PET ligands ([11C]2-beta-
carbomethoxy-3beta-(4-fluorophenyl) tropane ([11C]-CFT), [18F](2--carbomethoxy-
3-(4-fluorophenyl)tropane ([18F]-CFT, [18F] N-(3-fluoropropyl)-2beta-carbon 
ethoxy-3beta-(4-iodophenyl) nortropane ([18F]-FP-CIT), and [11C]-RTI-32) and 
SPECT tracers (such as [123I]-β-CIT, 123I-FP-CIT, [123I]-altropane, [11C]-
methylphenidate, and 99mTc-TRODAT-1). 
The SPECT tracer [123I]-β-CIT, a tropane derivative, binds to DAT, noradrener-
gic (NART), and serotonergic (SERT) transporters. DAT binding is estimated by 
striatal uptake at 24 h post-injection, whereas SERT binding by brainstem uptake at 1 
h post-injection. Striatal [123I]-β-CIT uptake, as [18F]-FDOPA uptake, correlates 
with disease stage and symptom severity in PD, particularly with bradykinesia but 
not rest tremor (Seibyl et al., 1995; Brücke et al., 1997; Pirker, 2003). The main dis-
advantage of [123I]-β-CIT is its slow striatal uptake kinetics. Since after administra-
tion, it takes 24 h to equilibrate in the striatum, SPECT must be delayed to the fol-
lowing day. Recently, new SPECT tracers such as [123I]-FP-CIT, 123I-altropane, 
and [123I]-PE21 have been developed; they have faster uptake kinetics (2 to 3 hours) 
though they give higher non-specific signals. Another SPECT tracer the 99mTc-
TRODAT-1 has the advantage of being technetium based and so available in kit 
form, however its specific signal is lower than the [123I] based SPECT tracers. 
DAT markers, as [18F]-FDOPA PET, differentiate early PD from normal sub-
jects with a sensitivity of around 90%. In early PD, as a response to dopamine cell 
loss, remaining DAT may be down-regulated in surviving neurons in order to pre-




terminal density in early PD. DAT binding, alike [18F]-FDOPA, decreases with age 
(Pirker et al., 2000; van Dyck et al., 1995). 
 
Measurement of the vesicular monoamine transporter 2 
 
The type-2 vesicular monoamine transporter (VMAT2), exclusively expressed in 
the brain, is responsible for the uptake of monoamines from the cytoplasm into the 
secretory vesicles in dopamine neurons (Liu and Edwards, 1997). Lee et al. com-
pared striatal uptake of [11C]-dihydrotetrabenazine ([11C]DTBZ), a PET tracer that 
binds to VMAT2, [18F]-FDOPA, and the DAT ligand [11C]-methylphenidate in PD. 
They found in the parkinsonian striatum, [18F]-FDOPA Ki relatively less reduced 
than the [11C]DTBZ binding potential, and [11C]DTBZ binding less reduced than 
[11C]-methylphenidate binding (Lee et al., 2000). This finding supports the presence 
of relative AADC up-regulation and DAT down-regulation in PD striatum in order to 
increase dopamine turnover and diminish its re-uptake. 
 
POST-SYNAPTIC DOPAMINERGIC IMAGING 
 
At least five dopamine receptor subtypes have been described so far, which are 
classified into two main categories: the D1 type receptors (D1 and D5), which stimu-
late the enzyme adenylate cyclase, and the D2 type receptors (D2, D3, D4), which 
are inhibitory. Post-synaptic dopaminergic PET and SPECT studies in PD have 
mainly focused on D2 dopamine receptors. 
[11C]-Raclopride, a low affinity dopaminergic D2 receptor ligand has been used 
in most PET studies to study postsynaptic dopamine receptors. In de novo, drug-
naïve PD patients, [11C]-Raclopride binding is either normal or increased in the pu-
tamen and normal in the caudate nucleus (Dentresangle et al., 1999; Rinne et al., 
1993). The increase of the putaminal binding at disease onset is usually interpreted in 
the frame of compensatory mechanism involving receptor up-regulation. In advanced 
PD, [11C]-Raclopride binding normalizes in the putamen and most often decreases in 
the caudate  (Antonini et al., 1994; Brooks et al., 1990, 1992; Dentresangle et al., 
1999; Turjanski et al., 1997). 
The expression of D2 and D3 receptors has been followed by the dopaminergic 
ligand, [11C]-FLB 457. They are reduced in the anterior cingulate, dorsolateral pre-
frontal and temporal cortex and the thalamus in late stage PD, suggesting lesions of 
the mesolimbic dopaminergic pathways that may be involved in the cognitive and 
emotional deficits in PD patients  (Kaasinen et al., 2000, 2003). 
The striatal binding of [123I]-iodobenzamide (IBZM), a SPECT ligand of dopa-
mine D2 receptors was found not to be altered in idiopathic drug-naïve PD patients 
(Schwarz et al., 1996). 
[11C]-SCH23390, a D1 receptor ligand, is normally taken up in the putamen of 
de novo drug-naïve PD patients and its binding may either be normal or reduced in 
more advanced and treated patients (Shinotoh et al., 1993; Turjanski et al., 1997). 
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2.2 Non-dopaminergic imaging and extrastriatal systems 
 
PD is a multi-system disease and the involvement of extrastriatal pathways in the 
disease process is now well established (Lang, 2007). Serotoninergic, noradrenergic 
and cholinergic neurons have been shown to be target of neurodegeneration soon in 
the disease process, indeed Lewy body pathology in noradrenergic, serotoninergic 
and cholinergic systems seems to be responsible for the onset of some non-motor 
symptoms in PD (Rodriguez-Oroz et al., 2009). 
 
SEROTONINERGIC AND NORADRENRGIC SYSTEMS 
 
Serotoninergic and noradrenergic systems have been investigated by [18F]-
FDOPA PET. AADC is present in all monoaminergic neurons terminals, therefore 
[18F]-FDOPA uptake in extrastriatal areas reflects the density serotoninergic and no-
radrenergic together with dopaminergic terminals. A recent [18F]-FDOPA cross-
sectional study on extrastriatal dopamine dysfunction in PD, showed in early PD 
raised [18F]-FDOPA uptake in midbrain raphe and reduced tracer uptake in locus 
coeruleus, while in advanced patients [18F]-FDOPA uptake decreased in both nuclei. 
Uptake into the red nucleus, subthalamus, ventral thalamus and pineal gland was also 
targeted in more advanced patients, whereas limbic areas, except for hypothalamus, 
were spared even in late disease (Moore et al., 2008).  
Serotoninergic system has been explored by [11C]-WAY-100635 PET, a marker 
of serotonin 5-HT1A receptors which act as autoreceptors on the soma of serotoner-
gic neurones in the median raphe. PD patients compared to healthy controls showed a 
25% reduction in binding of [11C]-WAY-100635 in the midbrain raphe, but the 
magnitude of reduction was independent of the presence of depression (Doder et al., 
2000). [11C]-DASB PET, a marker of brain serotonin transporter binding, revealed 
in advanced, non-depressed PD patients a binding reduction of 20–30% in all ex-
amined brain areas compatible with a modest, widespread loss of brain serotonergic 
innervation (Guttman, 2007). These studies, therefore, do not support a major role for 
serotonergic loss in PD depression. Noradrenergic and dopaminergic neurotransmis-
sion has been recently assessed in PD patients with depression, by means of [11C]-
RT132 PET. Depressed PD patients showed lower [11C]-RT132 binding in locus 
coeruleus and areas of the limbic system than non-depressed PD patients. In areas 
with low dopaminergic innervation such as locus coeruleus, [11C]-RT132 uptake 
mainly reflects the density of noradrenergic neurons. In limbic areas, such as the ven-
tral striatum and amygdala, [11C]-RT132 uptake reflects function of both dopami-
nergic and noradrenergic pathways (Remy et al., 2005). An important role for nora-
drenaline and limbic dopaminergic rather than serotonergic dysfunction in the patho-







Cholinergic deficiency in demented PD patients has been assessed by PET and 
SPECT. [123I]-BMV SPECT, an in vivo marker of the vesicular acetylcholine trans-
porter, showed in non demented PD patients reduced tracer uptake in the parietal and 
occipital cortex, whereas in demented PD a more severe global reduction of cortical 
binding similar to that seen in Alzheimer's disease patients occurs (Kuhl et al., 1996). 
Cortical acethylcholinesterase activity in PD has been assessed by [11C]-MP4A 
PET, revealing a loss of cholinergic function throughout the cortex in parallel with 
the loss of striatal dopaminergic function, demented PD cases showing the most se-
vere reductions (Hilker et al., 2005). [11C]-PMP PET was also used to assay cortical 
acethylcholinesterase activity in PD with and without dementia. As expected, PD pa-
tients with dementia (PDD) were characterized by the greatest reduction in cortical 
acetylcholinesterase activity. As compared to Alzheimer's disease patients PDD pa-
tients, although matched for dementia severity, showed a lesser reduction in choli-
nergic innervation, the lateral temporal cortex being selectively targeted (Bohnen et 
al., 2003). 
2.3 Brain metabolic imaging 
Molecular imaging techniques to localize and quantify abnormalities of brain 
energy metabolism have been used for many years to study the pathophysiology of 
neurodegenerative disorders. (Slosman and Pellerin, 2004; Herholz et al., 2004). 
In Parkinson‘s disease, presynaptic dopamine loss has been shown to be asso-
ciated with broader functional abnormalities involving cortico–striato–pallido–
thalamocortical (CSPTC) loops and related pathways (De Long and Wichmann, 
2007). Thus, nigrostriatal dysfunction, even if highly localized, is associated with 
disease-specific alterations on regional cerebral metabolism across the whole brain. 
[18F]FDG-PET, thanks to its capability to assess local synaptic activity as well 
as biochemical maintenance process, has been widely employed in the study of the 
pathophysiology of PD (Pellerin et al., 2007, Eidelberg, 2009). 
The first [18F]FDG-PET studies revealed 1) in hemiparkinsonian patients at an 
early stage of the disease, an increased metabolism in the lentiform nucleus (putamen 
and Globus pallidus) on the opposite side of the affected hemibody (Wolfson et al., 
1985) 2) in more severely affected patients with dementia, a decrease in cortical glu-
cose utilization, particularly in posterior and temporal parietal associative regions 
(Kuhl et al., 1984; Wolfson et al., 1985). 
Afterwords, network analysis of functional imaging data in PD revealed a specif-
ic abnormal spatial covariance pattern involving metabolic changes at key nodes of 
the CSPTC loops and related pathways (Eidelberg et al., 1994, 1997; Moeller et al., 
1999; Ma et al., 2007). 
The Parkinson‘s disease-related pattern (PDRP) is characterized by increased 
pallido–thalamic and pontine metabolic activity associated with relative reductions in 
premotor cortex, supplementary motor area (SMA), and in parietal association re-
gions (Figure 4) . PDRP has been detected in several patient population (Eckert et al., 
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2007), it shows a good test-retest reproducibility in individual subjects over hours to 
weeks (Ma et al., 2007), and its expression correlates with standardized motor ratings 
in different patient cohorts (Asanuma et al., 2006). Further PDRP expression discri-
minates between PD, atypical parkinsonian syndromes, and healthy control subjects 
in prospective FDG PET scans (Eckert et al., 2008). 
Network analysis was further used to explore pathophysiological changes at the 
basis of cognitive dysfunction in PD.(Huang et al., 2007). A PD-related cognitive 
pattern (PDCP) characterized by metabolic reductions mainly in medial frontal and 
parietal association regions, and relative increases in cerebellar cortex and dentate 
nuclei was identified (Figure 1.4). This cognitive pattern correlated with performance 
on neuropsychological tests of memory and executive functioning. The expression of 
the PDCP was found to increase stepwise in PD patients categorized by clinical crite-
ria for mild cognitive impairment (MCI) (Huang et al., 2008). 
 
 
Figure 1.4. PDRP and PDCP (from Poston, 2009) 
Besides network analysis, region of interest (ROI) analysis and voxel based mul-
tivariate analysis by Statistical Parametric Mapping (SPM), were used to explore 
brain metabolism in PD. Frontal and temporo-parietal hypometabolism has been do-
cumented in PD patients (Hu et al., 2000; Juh et al., 2005), although recent studies 
suggested that patients without cognitive impairment had limited areas of hypometa-
bolism in the frontal and occipital cortices, whereas in patients with mild cognitive 
impairment there were extensive areas of hypometabolism in the posterior cortical 
regions, including the temporo-parieto-occipital junction, medial parietal, and infe-





3. Molecular imaging biomarkers in PD 
PD distinctive motor features are characterized by an insidious onset and an in-
exorable but variable progression. Thus, in recent years much effort are directed to 
determine reliable and well validated biomarkers for PD to identify individuals ―at 
risk‖ before motor symptoms onset, accurately diagnose individuals at the threshold 
of clinical PD, and monitor PD progression throughout its course. Biomarkers of 
such a type, would dramatically improve patient care and accelerate research into 
both PD cause and therapeutics (Marek et al., 2008). 
Biomarkers are broadly defined as characteristics that are objectively measured 
and evaluated as indicators of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention (Biomarkers Definitions 
Working Group, 2001; De Gruttola et al., 2001). 
Biomarkers in clinical research and clinical care can be employed to the follow-
ing aims: 1) to measure the biologic activity of a disease, therefore providing useful 
information about the disease process; 2) as a diagnostic tools or to determine risk 
and prognosis; 3) to provide information about an intervention‘s mechanism or bi-
ologic activity in in-vitro models, animal studies, or early human clinical trials in 
therapy development and evaluation; 4) as surrogate endpoints (i.e. a subset of bio-
markers intended to substitute for clinical endpoints).  
Biomarkers for PD are critical to the understanding of disease cause and disease 
progression. In particular, biomarkers may provide a window to the premotor period 
of PD before typical symptoms are manifest, but while degeneration has already be-
gun (Marek and Jennings, 2009). Both pathology and imaging studies, indeed, dem-
onstrated that PD is characterized by a long period during which vulnerable neuronal 
populations are degenerating, but when typical motor symptoms have not yet devel-
oped. At the threshold of motor symptoms about 40–60% of dopamine neuronal 
markers have been lost (Fearnley and Lees,1991; Marek, 1999; Morrish et al., 1998). 
The duration of the premotor period is unclear, however imaging and pathology data 
suggest that it may last from 5 to 20 years. 
 
3.1 Dopaminergic imaging 
Molecular imaging of the presynaptic nigrostriatal function, because of its capa-
bility to assess the ongoing dopaminergic degeneration, has been widely used as 
biomarker in studies assessing early PD. Dopaminergic degeneration has been ex-
plored either with [18F]-FDOPA and/or with DAT tracers (Brooks et al., 1990; 
Asenbaum et al., 1997; Mozley et al., 2000; Frey et al., 1996; Booij et al., 1998; Innis 
et al., 1993; Vingerhoets et al., 1994). A good correlation has been found between 
dopamine neuron loss and [18F]-FDOPA uptake, although in a very small sample 
(Snow et al., 1993). In postmortem PD brain, DAT density has been shown to be re-
duced in the striatum (Kaufman et al., 1991; Niznik et al., 1991; Wilson et al., 1996). 
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Consistent with the expected PD pathology, reductions in [18F]-FDOPA, vesicular 
monoamine transporter type 2 and DAT ligand uptake have been found. In details, 
these imaging studies demonstrate asymmetric loss of dopaminergic uptake, with a 
greater loss in the putamen as compared to the caudate, and the imaging loss corre-
lates with worsening clinical symptoms in cross-sectional evaluation (Huang et al., 
2001; Booij et al., 2001; Fischman et al., 1998; Sawle et al., 1994; Seibyl et al., 1995; 
Frey et al., 2001; Scherfler et al., 2007). 
Many studies have demonstrated that imaging markers can identify individuals 
with typical motor PD, even in its early stages, however, if the main future applica-
tion of imaging biomarkers would be to assess premotor PD, studies must move 
―backwards‖ to focus on subjects at risk but not yet diagnosed. (Marek and Jennings, 
2009) (Figure 1.1). 
At present, the challenge is how to find at risk subjects. Individuals with one or 
more symptoms of parkinsonism and therefore with suspected, but not diagnosed, PD 
constitutes one way to identify subjects at risk for PD. Several studies have examined 
the accuracy of DAT imaging in subjects with nondiagnostic motor symptoms (Cata-
fau and Tolosa, 2004; Jennings et al., 2004; Tolosa et al., 2007). Imaging was com-
pared with a longitudinal ―gold standard‖ clinical diagnosis. Individuals with sus-
pected PD and reduced DAT density were demonstrated to be at very high risk for a 
clinical diagnosis of PD. These imaging markers, however, cannot distinguish be-
tween idiopathic PD and other parkinsonisms such as progressive supranuclear palsy, 
multiple system atrophy, cortical basal ganglionic degeneration, and diffuse Lewy 
body disease. To this aim, [18F]FDG PET by revealing changes in neural circuit di-
rectly or indirectly related to dopaminergic dysfunction, may be more useful in dis-
tinguishing PD from these Parkinson syndromes (Eckert et al., 2008). 
Dopaminergic imaging has also demonstrated its utility in clinical trials on very 
early PD. In untreated recently diagnosed PD, in vivo dopaminergic imaging has 
identified about 10–15% of enrolled subjects with scans in the normal range—termed 
scans without evidence of dopaminergic deficit (SWEDD) (Whone et al., 2002; Par-
kinson Study Group, 2004, 2007). Follow-ups subsequently demonstrated that those 
patients with SWEDD are unlikely to have PD, whereas those with DAT deficit are 
very likely to have PD (Marek et al., 2003) Therefore, dopaminergic imaging accu-
rately distinguishes subjects unlikely to have PD from those with an eventual clinical 
diagnosis of PD. 
Before the development of motor symptoms, early non-motor symptoms may re-
liably identify subjects at risk for PD, so that combined with imaging markers they 
may aid further defining premotor PD. Among early non motor features of PD, the 
ones more often described include loss of olfactory function, sleep disturbances (e.g., 
RBD), autonomic dysfunction such as constipation, and behavioral and cognitive 
changes (Langston, 2006; Siderowf and Stern, 2006; Tolosa et al., 2007). 
To identify premotor PD, early clinical manifestations and dopaminergic imaging 
have been recently considered together. Among PD relatives showing olfactory defi-
cit, DAT imaging identifies a sub-group with increased risk of developing PD (Pon-
sen et al., 2004). Similar findings have been reported by combining RBD and dopa-




Recent advances in molecular genetics, by uncovering several genes for PD, has 
provided new possibilities to identify at risk and premotor PD population (Klein and 
Schlossmacher, 2007; Pankratz et al., 2007). Genes mutations previously described 
generally account for a very small number of PD patients, on the contrary LRRK2 
mutations may identify approximately 20–35% of the PD patients in populations 
such as the Ashkenazi Jewish or in regional populations of Spain or North Africa 
(Ozelius et al., 2006; Saunders-Pullman et al., 2006; Lesage et al., 2006). In addition, 
thanks to initiatives as the International LRRK2 Consortium genetic, clinical, and 
imaging assessment have been combined to shed new light on premotor PD in genet-
ic PD subsets (Healy et al., 2008). Dopaminergic imaging has been demonstrated to 
be altered in unaffected family members of patients with PD who are gene-positive 
for LRRK2 and other Park gene abnormalities (Adams et al., 2005; Khan et al., 
2002). 
3.2 Non-dopaminergic imaging 
Recent growing interest is directed towards nondopaminergic imaging biomark-
ers for premotor PD, aimed to explore specific potential underlying pathophysiology 
of PD such as inflammation, α-synuclein deposition, mitochondrial dysfunction, or 
protein misfolding (Hirsch et al., 2003; Olanow and McNaught, 2006; Schapira et al., 
1998; Singleton et al., 2003). 
Inflammation has been proposed as a risk biomarker for PD by recent pathologic, 
imaging and epidemiologic studies, as a consequence imaging markers of inflamma-
tion may be an early marker of PD risk (Chen et al., 2005, 2008; McGeer and 
McGeer, 2004). Increased microglial activation in PD has been shown by [11C]-
PK11195 PET studies (Gerhard et al., 2006; Ouchi et al., 2005). 
Molecular genetics showed how increased α-synuclein could be a risk biomarker 
for PD (Winkler, 2007; Cookson and van der Brug, 2008; Ahn et al., 2008). Changes 
in the plasma and cerebral spinal fluid of PD patients have been revealed by α-
synuclein assays (El-Agnaf et al., 2006; Tokuda et al., 2006). Unfortunately, α-
synuclein imaging is as yet an unfulfilled goal. 
Early non-motor features of PD, such as olfactory deficits, sleep disturbances, 
autonomic dysfunction, and behavioral and cognitive changes, are most often not due 
to dopamine loss, but may involve pathology in norepinephrine, serotonin, choliner-
gic, or other neuronal systems. Nondopaminergic imaging biomarkers for early non 
motor clinical manifestations have begun to emerge. For example, cardiac imaging 
with [123I]-metaiodobenzylguanidine may identify early norepinephrine dysfunction 
in autonomic neurons (Spiegel et al., 2005; Oka et al., 2007). Serotonin dysfunction 
has been shown to be associated with depression in PD both by imaging and patho-
logic studies (Guttman et al., 2007). 
The growing burden of dementia in PD patients, has turned the interest to imag-
ing biomarkers to identify early cognitive dysfunction in PD. Markers of β-amyloid 
burden, glucose metabolism, or nicotinic receptor binding, have been suggested as 
tools that might identify prodromal sign of dementia in PD (Rowe et al., 2007; Fujita 
et al., 2006; Huang et al., 2007; Maetzler et al., 2008). 
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3.3 Brain metabolic imaging 
Metabolic brain imaging with [18F]FDG PET, thanks to its capability to assess 
regional synaptic activity has become an prominent biomarker for PD (Eidelberg et 
al., 1997). [18F]FDG-PET can be used both to study the pathophysiology of PD and 
to assess the treatment effects. 
Since localized dopaminergic pathology can alter functional connectivity across 
the entire brain in a disease-specific manner, spatial covariance methods have been 
used to identify metabolic abnormalities at the network level in PD (Eckert and Ei-
delberg, 2005; Eckert al., 2007). 
Network analysis of [18F]FDG-PET identified the previously described PDRP, 
which has been detected in seven independent patient populations (e.g., Moeller et 
al., 1999; Feigin.et al., 2002; Lozza et al., 2004; Eckert et al., 2007). Its expression in 
individual subjects has been demonstrated to be highly reproducible (Ma et al., 
2007). PDRP scores have also been used to discriminate between patients with PD 
and atypical parkinsonism (Ma et al., 2007; Eckert et al., 2007, 2008). In PD patients, 
pattern expression has been found to correlate with standardized motor ratings (Asa-
numa et al., 2006; Eidelberg et al., 1994, 1995), symptoms duration (Moeller and Ei-
delberg, 1997; Huang et al., 2007b), and intraoperative measurements of subthalamic 
nucleus (STN) firing rate (Lin et al., 2008). PDRP has therefore been proposed as a 
biomarker to differentiate PD patients from patients with atypical parkinsonism, and 
to assess longitudinal changes in disease-related motor disability. 
In addition to motor symptoms, voxel-based spatial covariance analysis of FDG 
PET has been used to identify a distinct PD-related metabolic pattern associated with 
cognitive dysfunction in non-demented patients, the PDCP, previously described 
(Huang et al., 2007a). Correlations between PDCP expression and performance in 
neuropsychological tests assessing memory and executive functions have been found 
(Huang et al., 2007a). The expression of this pattern has been shown to be greater in 
PD patients with mild cognitive impairment (MCI) compared to cognitively normal 
PD (Huang et al., 2008). PDCP, as PDRP, has been found to be highly reproducible 
in individual patients. However, unlike the PDRP, PDCP activity is not modulated by 
symptomatic treatment with levodopa or STN stimulation (Huang et al., 2007a; Hi-
rano et al., 2008). Moreover, the time course of PDCP expression in early stage dis-
ease is different from that of the PDRP (Huang et al., 2007b), with a slower, non-
linear trajectory that is unrelated to concurrent changes in motor function or striatal 
dopamine transporter (DAT) binding (Eckert et al., 2007b). The PDCP has been 
therefore suggested as a complementary network biomarker with specificity for early 
cognitive dysfunction in patients with PD. 
[18F]FDGF-PET has been used as biomarker to measures the pathologic 
processes associated with clinical disease progression. In a recent longitudinal study, 
[18F]FDG-PET was used in conjunction with dopaminergic imaging and UPDRS 
assessments to follow the change in network PDRP and PDCP activity in patients 
with early PD (Huang, 2007b). The development of PDRP expression over time was 
found to occur in parallel with progressive deterioration in UPDRS motor ratings and 
putamen DAT binding, whereas the progression of PDCP was found to progressively 




pared to PDRP(Huang, 2007b). Further, changes in PDCP activity did not correlate 
with concurrent declines in striatal DAT binding or increases in UPDRS motor rat-
ings. Thus, the two network measures of disease progression, the PDRP and the 
PDCP, have been regarded as distinct. These findings suggest that different underly-
ing pathophysiological networks could be associated with motor and cognitive dis-
ease progression in PD, and therefore the use of the PDCP has been proposed as a 
biomarker to assess cognitive changes in PD patients. 
The quantification of network activity was used also in the assessment of the 
clinical response to therapeutic intervention in PD (Eckert and Eidelberg, 2005). In-
formations obtained by comparing the changes in metabolic network activity during 
treatment, can indeed be used as biomarkers to identify the underlying pathological 
processes involved in observed clinical changes. Applications of such a type are fun-
damental in the development of novel PD treatments and in the assessment of inter-
vention efficacy. 
During dopaminergic treatment changes in both pallidal metabolism and PDRP 
network activity was found to correlated with clinical improvement in the UPDRS 
motor rating score (Feigin et al., 2001; Asanuma et al., 2006). During neurosurgical 
modulation of subthalamic nucleus (STN) activity a significant correlation between 
PDRP expression and intraoperative recordings of STN firing rate was found (Lin et 
al., 2008). The activity of this metabolic network may therefore be modulated by 
surgical interventions in this region. Indeed, FDG-PET studies have revealed sus-
tained reductions in PDRP expression following therapeutic STN lesioning (Su et al., 
2001; Trošt et al., 2003) as well as in PD cohorts treated with STN DBS (Asanuma et 
al., 2006; Trošt et al., 2006; Hirano et al., 2008). Overall, the metabolic changes re-
ported with STN DBS reflect normalization of the regional changes observed in un-
treated PD patients. Specifically, STN stimulation has been found to increase meta-
bolism in parietal association cortex and, to a lesser degree, in the prefrontal cortex 
(Trošt et al., 2006; Asanuma et al., 2006), regions with significant reduced metabol-
ism in untreated PD (Moeller et al., 1999; Eckert et al., 2007b). This suggests that the 
baseline metabolic reductions observed in these cortical regions are to some degree 
reversible. This may be attributable to a correction of overactive signaling in inhibi-
tory pallidal projections to a variety of thalamic relay nuclei (Taktakishvili et al., 
2002). 
Interestingly, the effects of levodopa and STN DBS on PDRP expression were 
not found to be additive (Asanuma et al., 2006). A ―floor effect‘‖ occurs, which does 
not allow to lower network activity beyond a naturally defined level determined by 
the effects of therapeutic STN lesioning. These findings suggest that upper and lower 
thresholds exist for therapeutic PDRP modulation. These bounds may define the min-
imum and maximum functional changes that are achievable with current interven-
tions. Whether interventions at other key PDRP nodes like the pedunculopontine 








The aim of this thesis was to explore brain function in drug-naïve Parkinson‘s 
disease patients by means of molecular imaging techniques. 
In detail: 
[18F]FDG-PET was employed to identify in drug-naïve PD patients brain meta-
bolic alteration uniquely related to disease process and not modulated by antiparkin-
sonian therapeutic intervention. To this aim changes in cerebral metabolic rate of 
glucose (CMRglc) in drug-naïve PD patients as compared to a group of normal con-
trols (NL) were assessed (Study 1). 
[18F]FDG-PET and [123I]FP-CIT SPECT were employed together to explore 
the early functional changes in brain function related to dopaminergic depletion in 
the putamen (Study 2) and in the caudate nucleus (Study 3). 
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Thirty-one consecutive PD patients (males 20, females 11; mean age 65,87 ± 
6,18 years; mean disease duration 18,58 ± 9,14 months) from the Neurological Clinic 
of the University of Florence were enrolled in this study. 
The inclusion criteria were 1) clinical diagnosis of possible PD according to Gelb 
criteria (Gelb, 1999) 2) striatal decrease in DAT density as measured with [123I]FP-
CIT SPECT. The exclusion criteria were 1) current or past assumption of any anti-
parkinsonian drugs 2) moderate cognitive impairment (Mini Mental State Examina-
tion < 24, MMSE; Folstein, 1975) 3) diagnosis of major depression 4) white matter 
microvascular disease and atrophy on brain MRI. 
Seventeen patients had predominant right-sided limb involvement, fourteen pa-
tients had predominant involvement of the left limbs. 
Before the beginning of a specific therapy for PD, patients underwent clinical as-
sessment, neuropsychological assessment, MRI, [123I]FP-CIT SPECT, [18F]FDG 
PET within a period of one month at our University Institution. 
2. Clinical and neuropsychological assessment  
Clinical severity of disease was assessed with Hoehn & Yahr (H&Y) scores 
(Hoehn and Yahr, 1967) and the motor part (part III) of the Unified Parkinson‘s Dis-
ease Rating Scale (UPDRS III) (Fahn et al., 1987). 
The neuropsychological assessment explored the following cognitive domains: 
executive functions (EF), attention and inhibition processes, memory and visuocon-
structional abilities. MMSE was administered to evaluate global cognitive function-
ing and to exclude patients with moderate cognitive decline. EF, attention and inhibi-
tion processes were explored by the Modified Card Sorting Test (MCST) (Nelson, 
1976), letter fluency (Novelli et al., 1986) and the Stroop Color Word Test (SCWT) 
(Spreen and Strauss, 1991). Visual short term memory (STM) was assessed by the 
Corsi Block Tapping Test (CBTT), verbal STM by Two Syllabic Word Repetition 
Test (TSWRT) and by the recency effect of the Serial Position Curve Test (SPCT), 
verbal long term memory (LTM) was assessed by the primacy effect of the SPCT 
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(Spinnler and Tognoni, 1987). Visuoconstructional abilities were assessed by Frag-
mented Figures Assembling Test (FFAT) (Spinnler and Tognoni, 1987). 
3. MRI 
MRI brain scan was performed on Gyroscan NT Intera (Philips Medical System, 
Europe) with T1-, T2-weighted, and FLAIR sequences (matrix 512x512, voxel size 
0,49x0,49x6,60mm). Images were reconstructed into 20 slices with 6 mm slice 
thickness in axial, coronal and sagittal orientation. 
4. [123I]FP-CIT SPECT 
All subjects underwent a [123I]FP-CIT SPECT scan. SPECT images were ac-
quired 3 hours after intravenous administration of [123I]FP-CIT (185 MBq) with a 3-
headed camera (IRIX, Philips Medical System, Europe) equipped with UHR collima-
tors. Images were acquired over 360° (120 angles, 40 projection/head,128 X 128 ma-
trix, bin size 2,33 mm); scanning time was of 60 sec/step and lasted 40 minutes. Im-
age data were reconstructed using OSEM algorithm into 128 slices (128x128 matrix, 
2.33 mm/pixel, 2.33 mm slice thickness). Attenuation correction was performed us-
ing Chang algorithm.  
5. [18F]-FDG PET 
Patients were injected with a dose of 370 MBq 
18
F-FDG, in resting state in a 
dimly lighted room with minimal background noise. Thirty minutes after [18F]-FDG 
administration, a scan lasting 20 minutes was acquired, using a GE PET device. A 
polycarbonate head holder was used to reduce head movements during the scan. 
Emission scans were acquired in two dimensional mode with an axial FOV of 15 cm 
and a planar FOV of 55 x 55 cm. Images were reconstructed by OSEM iterative algo-
rithm (2 iterations, 21 subsets). A transmission scan with 
68
Ge-sources was used for 
photon attenuation correction. Thirty-five PET slices were acquired using a 256x256 
matrix with a pixel dimension of 2.15 mm and slice thickness of 4.25 mm. 
6. Statistical Parametric Mapping (SPM) 
PET images were converted from DICOM into Analyze format using the 
MIPAV software and then processed using SPM2 (Study1) or SPM5 (Study 2 & 3) 
(Wellcome Department of Cognitive Neurology, Institute of Neurology, London) 
running on Matlab 7 (Mathworks, Inc., Natick, MA). A 12- parameter linear affine 
transformation and a non-linear three-dimensional deformation were applied to each 
subject scan to realign and spatially normalize images to a reference stereotactic 
template (Montreal Neurological Institute -MNI-, McGill University, Montreal, Que-




mm to account for individual variability in structure–function relation and to enhance 
signal to noise ratio. Global normalization was performed using the proportional 
scaling routine in SPM. The gray matter threshold was set to 0.8 of the mean and 
global calculation was obtained with respect to the mean voxel value. 
The appropriate SPM design was used for each study, in the context of the gen-
eral linear model. Coordinates of local maxima were converted from MNI to Talai-
rach space using the ―mni2tal‖ function (http://www.mrc-
cbu.cam.ac.uk/Imaging/Common/mnispace.shtml) and labeled according to the 
Talairach and Tournoux space (Talairach and Tournoux, 1988) by using the Talai-
rach Daemon Client Version 2.0 
(http://ric.uthscsa.edu/projects/talairachdaemon.html). 
 
Patients informed consent was obtained according to the Declaration of Helsinki 
and the local Ethical Committee approved the study. 
 
 
Chapter 4  




In recent years, attention has turned towards the potential applications of func-
tional neuroimaging in Parkinson‘s disease (PD). 
Dopaminergic imaging has become a prominent diagnostic tool in PD, but nigral 
cell loss is just one of several events in the disease progression and it may parallel the 
effects of disease in other brain areas (Michell et al., 2004; Braak et al., 2003). In this 
scenario, [18F]fluoro-deoxyglucose ([18F]FDG) PET, because of its capability to as-
sess changes in physiologically relevant neural systems, has been proposed as bio-
marker for PD, particularly to monitor disease progression and modulation effect of 
antiparkisonian therapy (Eckert et al., 2007; Asanuma et al., 2006). 
Until now, [18F]FDG-PET studies examining brain metabolic changes in PD 
mainly included, besides few drug-naïve patients, already treated patients in the ―off-
medication‖ condition (Asanuma et al., 2006; Ma et al., 2007). However in these 
washout designs a persistent medication effect on brain metabolism could not be 
completely ruled out. 
Thus, to assess the possible role of [18F]FDG-PET as a biomarker to monitor 
treatment effect, it is important to evaluate brain metabolic alterations in drug-naïve 
PD patients. Therefore this [18F]FDG-PET study explored alterations in cerebral 
metabolic rate of glucose (CMRglc) in drug-naïve PD patients. 
2. Methods 
2.1 Subjects 
The whole PD sample was included in study 1,i.e. thirty-one consecutive PD pa-
tients (Table 4.1).  
Twenty–five healthy and unmedicated sex- and age-matched normal subjects 
(NL) were recruited at New York University (NYU) (Table 4.1). Brain disease or 
cognitive disorders were excluded by MRI and detailed clinical and neuropsycholog-
ical examinations. 
Cristina Polito, Molecular imaging in Parkinson’s disease ISBN  978-88-6655-037-2  (print) 
ISBN  978-88-6655-041-9  (online) © 2011 Firenze University Press
Cristina Polito 24 
Table 4.1. Clinical characteristics of the study sample 
 NL (n=25) PD (n=31) p 
Gender 15 males, 10 females 21 males, 10 females n.s 
Age 64.13 ± 6.99 65.87 ± 6.18 n.s 
MMSE 29.40 ± 0.80 28.56 ± 1.58 < 0.05 
Disease duration (months) / 18.58 ± 9.14  
Side of symptoms onset / 17 right, 14 left   
Prevalent motor symptom / 21 tremor dominant 
10 non tremor dominant 
 
UPDRSIII / 13.58 ± 5.27  
H&Y (range) / 1-2  
Note: Values are mean ± SD; NL, normal subjects; PD, Parkinson‘s disease patients; MMSE, 
Mini Mental State Examination; UPDRS, Unified Parkinson‘s Disease Rating Scale; H&Y, 
Hoehn and Yahr. 
2.2 Statistical analysis 
Chi-square test and independent t-test were used to compare demographic and 
clinical data between PD and NL, and between PD subgroups (Right onset PD vs left 
onset PD, tremor dominant vs nontremor dominant PD), as appropriate. One-way 
ANOVA was used to determine if significant demographic and clinical differences 
existed between patients at different stages of PD. According to the Modified Hohen 
& Yahr stages (Jankovic et al., 1990) three groups were identified (i.e.Stage 1 = Uni-
lateral disease; Stage 1.5 = Unilateral plus axial involvement; Stage 2 = Bilateral dis-
ease, without impairment of balance.) P values <0.05 were considered significant. 
All statistical analysis were made using SPSS 15.0 (SPSS Inc., Chicago, IL). 
2.3 SPM 
The Two sample t-test was employed to explore CMRglc differences between 
PD patients and NL, and between PD subgroups (i.e. right-onset, left-onset, tremor-
dominant, non tremor-dominant) and NL. 
One-way ANOVA was performed to explore the main effect of disease severity, 
using disease stage as condition according to the Modified H&Y scale. Age was set 
as nuisance variable. The significance threshold was set to a corrected value of p < 
0.01 (False Discovery Rate, FDR, corrected). Coordinates of local maxima were la-






3.1 Demographic and clinical findings 
There were no demographic differences between PD patients and NL (Table 4.1). 
There were no differences between right- and left-onset PD subgroups for motor 
dominant symptom, mean disease duration, UPDRSIII and H&Y scores, while left-
onset PD were older than right-onset PD. In the right-onset PD group there were 
more males than females (p<0.05). There were no differences between tremor-
dominant and non tremor-dominant PD patients for age, gender distribution, side of 
symptoms onset, mean disease duration, UPDRSIII and H&Y scores. As expected, 
PD patients at different H&Y stages showed significant increases in UPDRSIII at 
advanced H&Y stages, while there were not demographic differences between 
groups. 
3.2 SPM results 
As compared to NL, PD patients showed hypometabolism in premotor area (PM, 
BA 6), dorsolateral prefrontal cortex (DLPFC, BA 46, 47), inferior temporal gyrus 
(ITG, BA 37), superior and inferior parietal lobule (SPL and IPL, BA 7, 39), inferior 
and middle occipital gyrus (IOG and MiOG, BA 18, 19) bilaterally (p<0.01 FDR cor-
rected). As compared to NL, PD patients showed hypermetabolism in lentiform nuc-
leus (LN), primary motor area (PMA, BA 4) and cerebellum of both hemispheres. 
The same pattern of CMRglc changes was observed in the comparisons between 
right-onset PD versus NL, and left-onset PD versus NL, but with a greater cluster ex-
tent in brain regions contralateral to the first affected body side. Both tremor-
dominant and non tremor-dominant PD, as compared to NL, respectively showed the 
CMRglc alterations seen in the whole group analysis. The one-way ANOVA con-
firmed a significant main effect of disease severity bilaterally in PM, PMA, DLPFC, 
ITG, SPL, IPL, IOG, MiOG, LN and cerebellum. Post hoc analysis revealed a pro-
gressive CMRglc reduction in PM, DLPFC, ITG, SPL, IPL, IOG, MiOG and a pro-
gressive CMRglc increase in PMA, LN and cerebellum (Table 4.2, Figure 4.1). 
Cristina Polito 26 
 
Table 4.2. Brain regions showing significant CMRglc differences in PD patients as compared 
to NL subjects. 
Cluster 
extent  
Anatomic area  Functional area  
Talairach Coordinates 
z 
x y z 
PD < NL 
9696 
Left Inferior Parietal Lobule BA 39 
-50 -71 11 6.16 
 Left Inferior Temporal Gyrus BA 37 -56 -58 -4 6.03 
 Left Inferior Temporal Gyrus BA 37 -50 -67 3 5.91 
 Inferior Occipital Gyrus BA 18 -35 -90 -8 4.41 
4679 
Right Precentral Gyrus BA 6 
62 4 24 5.21 
 Right Middle Frontal Gyrus BA 46 52 27 25 5.08 
 Right Middle Frontal Gyrus BA 47 50 38 -6 4.91 
4763 Left Inferior Frontal Gyrus BA 47 -42 26 -9 4.99 
 Left Precentral Gyrus BA 6 -45 0 24 4.85 
 Left Middle Frontal Gyrus BA 47 -45 40 -5 4.64 
4752 Right Inferior Temporal Gyrus BA 37 48 -63 1 4.74 
 Middle Occipital Gyrus BA 19 45 -70 -4 4.01 
1009 Right Superior Parietal Lobule BA 7 14 -71 41 4.22 
PD > NL 
9895 Left cerebellum Culmen -6 -41 -18 5.12 
 Right cerebellum Culmen 14 -52 -15 4.80 
1970 Right Lentiform Nucleus  29 -17 11 5.01 
894 Left Lentiform Nucleus  -26 -17 12 4.83 
54 Right Precentral Gyrus BA 4 24 -15 48 3.68 
181 Left Precentral Gyrus BA 4 -12 -22 64 3.67 
P < 0.01 FDR corrected 
Note: Values are mean ± SD; NL, normal subjects; PD, Parkinson‘s disease patients; MMSE, 
Mini Mental State Examination; UPDRS, Unified Parkinson‘s Disease Rating Scale; H&Y, 





Figure 4.1. Brain metabolic alterations in drug-naïve PD patients as compared to normal sub-
jects. 
 
Legend: Statistical parametric maps showing CMRglc reductions (a) and increases (b) in 
drug-naïve PD patients as compared to normal controls. Areas of hypometabolism and 
hypermetabolism are displayed on a standardized spatially normalized MRI. 
 
 
Chapter 5  
Study 2 Brain metabolic correlates of dopaminergic degeneration 
in de novo idiopathic Parkinson’s disease 
 
1. Background 
The cardinal pathological feature of PD is the degeneration of dopaminergic ni-
grostriatal neurons in the substantia nigra pars compacta, resulting in a loss of dopa-
minergic terminals in the striatum (Fearnley and Lees, 1991). SPECT and PET imag-
ing has been widely used to reveal abnormalities in dopaminergic transmission, par-
ticularly in the diagnostic phase (Seibyl et al., 2003). Nigrostriatal dopaminergic neu-
ronal loss in PD is, however, the cardinal of several neuro-functional steps in the 
pathologic progression of the disease(Bezard et al., 2003;  Braak et al., 2003; Obeso 
et al., 2004). Previous [18F]-FDG PET studies showed a characteristic pattern of re-
gional glucose metabolism (rCMRglc) in patients with PD compared to controls, in-
volving frontal and temporo-parietal-occipital hypometabolism, together with in-
creased pallido-thalamic, pontine and cerebellar activity (Eckert et al., 2005b; Eidel-
berg et al., 1994; Fukuda et al., 2001; Huang et al., 2007b). Besides, several studies 
showed the correlation between reduced rCMRglc and severity of motor impairment 
in PD, demonstrating an inverse correlation involving in particular anterior cingulate 
gyrus, orbitofrontal and occipitotemporal regions (Nagano-Saito et al., 2004). 
The study of the relation between the severity of dopaminergic degeneration, as 
assessed with [123I]-FP-CIT SPECT, and metabolic dysfunction in PD patients, as 
assessed by [18F]FDG-PET might reveal in which regions rCMRglc changes are di-
rectly related to the dopaminergic neuronal loss. To this aim, an accurate measure-
ment of dopaminergic degeneration plays a key role and the enrolment of drug naïve 
PD patient is mandatory. Indeed, in de novo PD patients the pathological processes 
are not yet affected by pharmacological agents (Fahn et al., 2004), allowing a more 
accurate insight of PD processes. 
The present study evaluates in drug-naïve PD patients the relation between the 
brain metabolic changes, measured with [18F]-FDG PET, and the severity of dopa-
minergic degeneration, assessed with [123I]-FP-CIT SPECT. Striatal [123I]-FP-CIT 
uptake was quantified with the Binding Potential measurement (Tissingh et al., 1998; 
Innis et al., 2007), estimated by the Least Squares (LS) method, an algorithm previ-
ously developed in our Institute, which allows to obtain BP estimates that are less af-
fected by partial volume effects (PVE) and its reliability has been validated in phan-
tom (Vanzi et al., 2007) and clinical studies (Berti et al., 2008).  
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2. Methods 
2.1 Subjects 
Twenty-six PD patients of the whole drug-naïve PD sample were included in this 
study (17 males and 9 females, mean age: 65.3±6.4 years) (Table 5.1). They were ex-
amined with MRI scan, [123I]-FP-CIT SPECT and [18F]-FDG PET. 
Table 5.1. Patients‘ demographic and clinical data  
Demographics  Value  
Age (years)  65 ± 6 [53-77]  
Sex  17 males, 9 females  
Side of motor symptoms onset  13 right, 13 left  
Symptom at onset 20 tremor, 6 brad/rig 
Disease duration (months)  19 ± 9 [3-36]  
UPDRS III score  14 ± 5  [7-27]  
H&Y score  1.6 ± 0.4  [1-2.5]  
Note: values are mean ± standard deviation [range]  
2.2 Image analysis 
Each MRI scan was coregistered with the corresponding SPECT scan recon-
structed with the OSEM algorithm by using a 3D method based on rigid transforma-
tion with correlation ratio as cost function implemented in Medical Image Process-
ing, Analysis and Visualization (MIPAV version 3.1.3, National Institutes of Health, 
NIH, Bethesda, MD). Coregistered MRI/SPECT images consisted in axial sections of 
128 slices (128x128 matrix, 2.33 mm/pixel, 2.33 mm slice thickness). 
ROIs were manually segmented on the coregistered MRI images on right and left 
caudate nucleus (NC) and right and left putamen, and on cerebellum. These ROIs 
were rigidly repositioned on [123I]FP-CIT SPECT and used to quantify striatal BP 
by means of Least Squares (LS) method (Formiconi et al., 1993; Vanzi et al., 2007). 
Striatal BP was estimated as the ratio of a region of specific binding (striatum) to 
a region of non-specific binding (cerebellum). We estimated BP for right and left 
caudate nucleus and right and left putamen separately. 
Among all striatal regions, putaminal BP was identified as the most accurate 
measure to determine the severity of dopaminergic degeneration (Spiegel et al., 
2007; Isaias et al., 2007) and therefore used to test the correlation with the clinical 






The Multiple Regression Design was employed to explore regions in which 
rCMRglc correlates negatively with UPDRS III and positively with putaminal BP. 
The SPM{t} maps were obtained at a height threshold of p < 0.005, cluster extent ≥ 
50 voxels. Correction for multiple comparisons was conducted using SPM‘s Small-
Volume-Correction (SVC) facility (Worsley et al., 1996) across the frontal lobe, 
based on the a priori knowledge of the physiology of fronto-striatal circuits (Alexan-
der et al., 1986, 1990) and of the regional pattern of metabolic changes in PD, which 
involves prefrontal regions (Fukuda et al., 2001). The significance threshold was set 
to a corrected value of p<0.05 (False Discovery Rate, FDR, corrected).   
3. Results 
Caudate and putaminal BP values are shown in Table 5.2.  
Table 5.2. Striatal BP values 
Striatal region BP 
Right caudate nucleus 6.98 ± 1.88  
Left caudate nucleus 6.86 ± 1.90  
Right putamen 4.59 ± 1.33  
Left putamen 4.54 ± 1.33  
Ipsi caudate nucleus 7.20 ± 1.82 
Contr caudate nucleus 6.64 ± 1.91 
Ipsi putamen 5.05 ± 1.36 
Contr putamen 4.09 ± 1.36 
Note: values are mean ± standard deviation [range] 
SPM analysis demonstrated a negative correlation between UPDRS III scores 
and rCMRglc in bilateral premotor cortex (PMC, Brodmann Area-BA 6) (Table 5.3). 
The clusters did not survive after SVC correction for multiple comparisons.  
Right putaminal BP positively correlated with rCMRglc in bilateral DLPFC (BA 
9), bilateral PMC (BA 6) and bilateral anterior prefrontal cortex (APFC, BA 10) (Ta-
ble 5.3) (Figure 5.1). After SVC correction for multiple comparison, right putaminal 
BP positively correlated with rCMRglc in right DLPFC (BA 9), right PMC (BA 6) 
and right APFC (BA 10). 
Left putaminal BP positively correlated with rCMRglc in bilateral DLPFC (BA 
9), bilateral PMC (BA 6), bilateral APFC (BA 10) and bilateral orbitofrontal cortex 
(OFC, BA 11) (Table 5.3) (Figure 5.1). After SVC correction for multiple compari-
Cristina Polito 32 
son, left putaminal BPLS positively correlated with rCMRglc in left DLPFC (BA 9), 
left PMC (BA 6), left APFC (BA 10) and left OFC (BA 11). 
 









x y z 
UPDRS III 
negative 
       
 94 Left Frontal lobe GFm BA 6 -26 15 62 3.91 
  Left Frontal lobe GFs BA 6 -16 22 60 3.67 
  Left Frontal lobe GFs BA 6 -18 13 64 3.17 
 113 Right Frontal lobe GFs BA 6 22 -6 70 3.62 
  Right Frontal lobe GFs BA 6 16 3 68 3.51 
Right putaminal BPLS 
positive 
       
 2552 Right Frontal lobe GFs BA 9 16 48 25 4.93* 
  Right Frontal lobe GFd BA 10 2 51 9 4.47* 
  Right Frontal lobe GFs BA 10 12 66 2 4.30* 
 2035 Right Frontal lobe GFi BA 6 55 0 24 4.77* 
  Right Frontal lobe GFm BA 9 50 25 32 4.72* 
 1251 Left Frontal lobe GPrC BA 9 -44 21 36 4.63 
  Left Frontal lobe GPrC BA 6 -53 0 35 4.43 
 178 Left Frontal lobe GFm BA 10 -38 53 10 4.15 
Left putaminal BP 
positive 
       
 1332 Left Frontal lobe GPrC BA 9 -46 21 36 5.62* 
  Left Frontal lobe GFm BA 9 -24 32 26 4.69* 
  Left Frontal lobe GPrC BA 6 -48 0 33 4.62* 
 454 Right Frontal lobe GFs BA 11 8 59 -21 4.98 
  Left Frontal lobe GFs BA 11 -2 57 -21 3.77* 
  Left Frontal lobe GFs BA 11 -12 66 -10 3.63 
 125 Left Frontal lobe GFm BA 10 -38 51 9 3.77* 
 362 Right Frontal lobe GPrC BA 6 55 2 31 3.75 
 175 Left Frontal lobe GFs BA 9 -18 58 27 3.65 
  Left Frontal lobe GFs BA 10 -12 61 23 3.42 
 675 Right Frontal lobe GFd BA 10 4 51 5 3.47 
  Right Frontal lobe GFd BA 9 20 42 22 3.43 
 101 Right Frontal lobe GR BA 11 4 32 -20 3.31 
Note: * Survived at SVC correction for multiple comparisons (p<0.05).  
Abbreviations: GFm=middle frontal gyrus; GFs=superior frontal gyrus; GFi=inferior frontal 





Figure 5.1 Regions with significantly positive correlation with right (a) and left (b) 
BP in the [18F]-FDG study 
 
 
Chapter 6  
Study 3 Functional changes related to dopamine depletion in the 
caudate nucleus in early Parkinson’s disease 
 
1. Background 
PD is a neurodegenerative disorder, in which, besides characteristic motor symp-
toms, cognitive deficits ranging from mild cognitive impairment to genuine dementia 
often occur (Caviness et al., 2007; Riedel et al., 2008). Functional neuroimaging 
plays a key role in the understanding of mechanisms underlying both motor and non 
motor dysfunction in PD (Nandhagopal et al., 2008). 
The cardinal neuropathological feature of PD is the degeneration of nigrostriatal 
dopaminergic (DA) neurons, resulting in a loss of DA terminals in the striatum 
(Fearnley and Lees, 1991). [123I]FP-CIT SPECT imaging is the diagnostic technique 
most widely used to clinically assess DA system impairment (Booij et al., 2001). Be-
sides, in PD patients correlations have been found between DA depletion in the cau-
date nucleus (NC) and the degree of dementia (Rinne et al., 1989) and neuropsy-
chological performance (Brück et al., 2001, 2005; Marie et al., 1999), although these 
findings have not been always confirmed (Broussolle et al., 1999; Rinne et al, 2000). 
On the other side, [18F]FDG PET, has been used to identify regional changes in 
brain function that differentiate PD patients with and without cognitive dysfunction 
(Huang et al., 2008). Several studies identified a metabolic pattern associated with 
cognitive dysfunction in PD characterized by metabolic reductions in frontal and pa-
rietal association areas with relative increases in the cerebellar vermis and dentate 
nuclei (Huang et al., 2007). 
DA transporter imaging (FP-CIT SPECT imaging) and brain metabolic imaging 
(FDG PET imaging) have been broadly employed to explore the biological substrate 
of PD, but the information of these two widespread molecular imaging techniques 
has been long considered apart. In study 2 we investigated the relation between the 
severity of DA degeneration in the putamen and metabolic dysfunction in early drug 
naïve PD patients (Berti et al., 2009), thus focusing on the functional changes occur-
ring in motor basal ganglia cortical circuit. Besides the metabolic changes in ex-
pected motor cortical regions, we found changes in associative and limbic regions, 
such as dorsolateral prefrontal, anterior prefrontal and orbitofrontal areas, hence sug-
gesting an early involvement of non motor frontostriatal circuit in PD. 
Given the central role of NC in cognitive dysfunction in PD (Grahn et al., 2008), 
the study of the direct relation between DA depletion severity in NC, brain metabo-
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lism and cognitive functions in early drug naïve PD patients could reveal the early 
functional changes directly related to NC DA depletion in associative frontostriatal 
circuit, in the absence of the modulation effect of anitiparkinsonian treatment both on 
brain metabolism (Asanuma et al, 2006) and cognitive functions (Cools, 2006). 
Therefore in the present study, we investigate the direct relation between DA de-
generation severity in NC, assessed by [123I]FP-CIT SPECT NC BP, brain meta-
bolic dysfunction, assessed by [18F]FDG PET rCMRglc, and cognitive dysfunction 
in de novo PD patients.  
2. Methods 
2.1 Subjects 
Twenty five drug naïve non demented PD patients of the original PD sample 
were enrolled in this study. 
Demographic data, disease duration, motor symptoms onset side, UPDRS III 
scores, H&Y scores, neuropsychological data are shown in Tables 6.1, 6.2. 
Table 6.1. Patients characteristics 
No of subjects 25 
Sex  17 males, 8 females  
Age (years)  65.60 ± 6.34 [53-77]  
Education 7.44 ± 3.30 [5-18] 
Side of motor symptoms onset  12 right, 13 left  
Disease duration (months)  19.52 ± 9.44 [3-36]  





Table 6.2 Clinical and neuropsychological data 
UPDRS III  14.44 ± 5.48 [7-27] 
H&Y  1.6 ± 0.4 [1-2.5] 
MMSE 28.69 ± 1.63 [24.27-30] 
MCST PE 5.09 ± 7.63 [0-35] 
MCST NPE 3.52 ± 4.79 [0-16] 
MCST TE 9.04 ± 10.34 [0-36] 
MCST Categories 5.08 ± 1.60 [2-6] 
Letter fluency 31.32 ± 9.14 [16-48.5] 
SCWT A 19.68 ± 7.11 [11-44] 
SCWT B 27.96 ± 10.07 [11-47] 
SCWT C 42.56 ± 16.00 [19-80] 
CBTT 5.42 ± 1.01 [4-7.25] 
TSWRT 4.35 ± 0.72 [3-5.63] 
SPCT Primacy effect 3.67 ± 2.10 [0-7.50]  
SPCT Recency effect 13.64 ± 4.65 [3-20] 
FFAT 9.06 ± 3.31 [0.75-13.75] 
Note: Values are mean ± standard deviation [range] 
UPDRS III, Unified Parkinson‘s Disease Rating Scale part III; H&Y, Hoehn and Yahr; 
MMSE, Mini Mental State Examination; MCST PE, NPE, TE, Modified Card Sorting Test 
perseverative errors, non perseverative errors, total errors; SCWT A, B, C, Stroop Color Word 
Test, part A, part B, part C; CBTT, Corsi Block Tapping Test; TSWRT, Two Syllabic Word 
Repetition Test; SPCT, Serial Position Curve Test; FFAT, Fragmented Figures Assembling 
Test. 
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2.2 Image analysis 
Each MRI scan was coregistered with the corresponding SPECT scan recon-
structed with the OSEM algorithm by using a 3D method based on rigid transforma-
tion with correlation ratio as cost function implemented in Medical Image Process-
ing, Analysis and Visualization (MIPAV version 3.1.3, National Institutes of Health, 
NIH, Bethesda, MD). Coregistered MRI/SPECT images consisted in axial sections of 
128 slices (128x128 matrix, 2.33 mm/pixel, 2.33 mm slice thickness). 
ROIs were manually segmented on the coregistered MRI images on right and left 
NC and right and left putamen, and on cerebellum. These ROIs were rigidly reposi-
tioned on [123I]FP-CIT SPECT and used to quantify striatal BP by means of Least 
Squares (LS) method. The LS method, a reconstruction algorithm developed in our 
Institute (Formiconi, 1993), validated in phantom (Vanzi et al., 2007) and clinical 
studies (Berti et al., 2008), was used to estimate striatal BP since it allows a quantifi-
cation of striatal [123I]FP-CIT BP scarcely affected by partial volume effects (Vanzi 
et al., 2007), and it was demonstrated to be a sensitive parameter to explore correla-
tions with rCMRglc relative to traditional reconstruction algorithms (Berti et al., 
2009). 
Striatal BP was estimated as the ratio of a region of specific binding (striatum) to 
a region of non-specific binding (cerebellum). We estimated BP for right and left NC 
and right and left putamen separately. 
Among striatal regions, right and left NC BP separately were used to test the cor-
relation with neuropsychological test scores and with rCMRglc, according to the 
classical model of basal ganglia functional organization which maintains NC as the 
striatal relais of non motor associative loop (Alexander et al, 1986). 
2.3 Statistical analysis 
For normality testing, Kolmogorov-Smirnov test and Shapiro-Wilk test were 
used, as appropriate. Independent t test was used to compare NC and putamen BP. 
Spearman‘s rho correlation coefficient was used to determine the relationship be-
tween NC BP values and neuropsychological tests scores. Values of p < 0.05 were 
considered statistically significant.  
2.4 SPM 
The Multiple Regression Design was employed to explore regions in which 
rCMRglc correlates with neuropsychological test scores and with right and left NC 
BP separately. Among neuropsychological test, the following tests were selected for 
the SPM multiple regression analysis: MCST perseverative errors and letter fluency 
for EF, SCWT C for attention and inhibition process, SPCT primacy effect for LTM, 
SPCT recency effect for STM, FFAT for visuoconstructional abilities. The SPM{t} 
maps were obtained at a height threshold of p < 0.005, cluster extent ≥ 50 voxels. 
Correction for multiple comparisons was conducted using SPM‘s Small-Volume-




(DLPFC), anterior prefrontal cortex (APFC), orbitofrontal cortex (OFC), based on 
the a priori knowledge of the physiology of fronto-striatal non motor circuits (Alex-
ander et al, 1986; Alexander and Crutcher, 1990) and across prefrontal, posterior pa-
rietal and cerebellar regions based on the regional pattern of metabolic changes asso-
ciated with cognitive dysfunction in PD (Huang et al., 2007). The significance 
threshold was set to a corrected value of p < 0.05 (False Discovery Rate, FDR, cor-
rected). 
3. Results 
3.1 [123I]FP-CIT SPECT and neuropsychological findings 
NC and putaminal BP values are shown in Table 6.3. 
Table 6.3 [123I]FP-CIT SPECT Binding Potential (BP) 
Right NC BP 6.86 ± 1.82 [3.58-9.94] 
Left NC BP 6.73 ± 1.81 [3.24-9.87] 
Ipsilateral NC BP 7.20 ± 1.76 [4.03-9.94] 
Contralateral NC BP 6.39 ± 1.78 [3.24-9.87] 
Right putaminal BP 4.48 ± 1.48 [0.26-6.87] 
Left putaminal BP 4.45 ± 1.31 [1.33-6.89] 
Ipsilateral putaminal BP 4.96 ± 1.30 [1.33-6.89] 
Contralateral putaminal BP 3.98 ± 1.29 [0.26-6.23] 
Note: Values are mean ± standard deviation [range] 
NC: caudate nucleus. 
There is no significant difference between BP values of right and left NC and of 
right and left putamen. Considering the first and most affected side of motor symp-
toms, the BP values in the contralateral putamen to the most affected body side (3.98 
± 1.29) were significantly lower than BP values in the ipsilateral putamen (4.96 ± 
1.30) (p < 0.01). Contralateral NC BP values had a lower mean as compared to ipsi-
lateral NC BP values (6.39 ± 1.78 vs 7.20 ± 1.76), however this difference did not 
reach statistical significance (p = 0.11). Putaminal BP values were significantly 
lower than NC BP values, both in the ipsilateral and contralateral side ( 4.96 ± 1.30 
vs 7.20 ± 1.76, p < 0.0001, and 3.99 ± 1.29 vs 6.39 ± 1.78 p < 0.0001 respectively). 
There was a significant correlation between right NC and right putamen (r = 0.769, p 
< 0.0001), left NC and left putamen (r = 0.699, p < 0.0001), ipsilateral NC and ipsi-
lateral putamen (r = 0.693, p < 0.0001), contralateral NC and contralateral putamen (r 
= 0.791, p < 0.0001). 
None of the patients complained of subjective cognitive deficits, even so com-
pared to available normative data impairment in both EF and memory domains were 
observed (14 patients), as well as selective deficits in EF (one patients) and memory 
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(7 patients). Only three patients showed no cognitive impairment, nevertheless no 
significant correlation was found between right and left NC BP and neuropsy-
chological test scores. 
3.2 Correlation with rCMRglc 
As concerns the correlation with neuropsychological measures SPM analysis re-
vealed that rCMRglc correlated: (1) negatively with MCST perseverative errors in 
right premotor cortex (PMC, BA 6); (2) positively with letter fluency in bilateral 
OFC (BA 10), DLPFC (BA 9, BA 46), right primary motor area (PMA, BA 4) and 
PMC (BA 6), (3) negatively with SCWT part C in left PMC (BA 6), right PMA (BA 
4) and right primary auditory area (BA 41); (4) positively with the SPCT primacy ef-
fect in left extrastriate visual association area (BA 19), and in right cerebellar poste-
rior lobe; (5) positively with SPCT recency effect in right postcentral gyrus (BA 43), 
PMC (BA 6) and in left insula (BA 13); (6) positively with FFAT in left thalamus 
and left OFC (BA 47). None of these clusters survived FDR SVC correction for mul-





Table 6.4 List of local maxima of the most significant correlations between neuropsychologi-
cal test scores and rCMRglc. 
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 86 R Middle Frontal Gyrus BA46 44 44 25 3.32 
 96 R Middle Frontal Gyrus BA 10 40 58 -10 3.21 
 121 L Superior Frontal Gyrus BA 10 -20 66 23 4.00 
 143 L Middle Frontal Gyrus BA 9 
L Superior Frontal Gyrus BA 9 



























 90 R Superior temporal gyrus BA 41 45 -34 13 3.36 
 54 L Middle Frontal Gyrus BA 6 -38 14 59 3.57 














 124 L Superior occipital gyrus BA 19  48 -67 -29 3.47 














  R Precentral Gyrus BA 6 54 1 11 4.48 
 57 L Insula BA 13 -43 -24 16 3.19 
5. FFAT 













 237 L Orbital Gyrus BA 47 -12 20 -26 3.94 
p value < 0.005 uncorrected 
Note: MCST PE, Modified Card Sorting Test perseverative errors; SCWT C, Stroop Color 
Word Test part C; SPCT, Serial Position Curve Test; FFAT, Fragmented Figures Assembling 
Test; R, Right; L, Left. 
As concerns NC BP correlation, SPM analysis revealed a positive correlation be-
tween right NC BP and rCMRglc in bilateral anterior cingulate cortex (ACC, BA 
32), OFC (BA 10, 11, 47), DLPFC (BA 9), superior and middle temporal gyrus (BA 
38, 21), while left NC BP correlated with rCMRglc in bilateral ACC (BA 32), OFC 
(BA 10, 11), DLPFC (BA 9) and right middle temporal gyrus (BA 38). All these 
clusters survived the FDR SVC correction for multiple comparisons (Table 6.5, Fig-
ures 6.1 and 6.2). Middle temporal regions were not included in our a priori hypothe-
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sis based on frontostriatal circuits so a post hoc SVC correction was performed based 
on network connecting NC and ventral striatum to middle temporal regions, demon-
strated by recent MRI tractography studies (Leh et al., 2007). 
Table 6.5 List of local maxima of the most significant correlations between NC BP and 
rCMRglc. 
Note: NC, caudate nucleus; BP, Binding Potential; R, Right; L, Left. 
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  R Superior Frontal Gyrus BA 11 14 61 -18 4.76 
  R Rectal Gyrus BA 11 4 34 -20 4.66 
 359 R Superior Frontal Gyrus BA 9 46 40 31 4.08 
 108 R Inferior Frontal Gyrus BA 47 42 21 -4 4.07 
 201 L Middle Frontal Gyrus BA 9 -44 35 31 3.89 
 50 L Middle Frontal Gyrus BA 10 -44 35 31 3.34 
 335 R Superior Temporal Gyrus BA 38 40 10 -34 5.19 
 219 L Middle Temporal Gyrus BA 21 -42 8 -34 3.37 














 518 R Superior Frontal Gyrus BA 11 12 59 -21 4.85 
  R Rectal Gyrus BA 11 2 32 -20 4.22 
 942 R Medial Frontal Gyrus BA 10 10 43 11 4.76 
 341 R Superior Frontal Gyrus BA 9 46 40 31 3.80 
 537 L Superior Frontal Gyrus BA 9 -40 36 29 3.87 
  L Middle Frontal Gyrus BA 10 -36 51 10 3.43 
 190 R Middle Temporal Gyrus BA 38 42 8 -36 4.71 






Figure 6.1 Direct correlation between rCMRglc and right NC BP. (A) Significant clusters pro-
jected on the standardized MNI MRI render surface, (B) Significant cluster projected on stan-
dardized MNI MRI axial slices, (C-F) Regression analysis of rCMRglc response as dependent 
variable and right caudate BP as independent variable at most significant clusters.NC; caudate 
nucleus. 
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Figure 6.2 Direct correlation between rCMRglc and left NC BP. (A) Significant clusters pro-
jected on the standardized MNI MRI render surface, (B) Significant clusters projected on 
standardized MNI MRI axial slices, (C-F) Regression analysis of rCMRglc response as de-






The aim of this thesis was to explore the early functional brain changes characte-
ristic of drug naïve PD patients by means of molecular imaging techniques, and spe-
cifically [123I]FP-CIT SPECT and [18F]FDG PET.  
1. Brain metabolism in drug naïve PD patients 
In study 1 we investigated brain metabolism in drug-naïve PD patients, in order 
to explore CMRglc alterations uniquely related to disease process and not modulated 
by antiparkinsonian treatment. 
Drug-naïve PD patients showed several CMRglc alterations as compared to NL, 
characterized by hypometabolism in frontal (PM, DLPFC) and temporo-parieto-
occipital regions (ITG, SPL, IPL, IOG, MiOG), and hypermetabolism in motor 
(PMA), lentiform and cerebellar regions. Interestingly, these metabolic changes were 
confirmed independently of symptoms onset side and of prevalent motor symptom. 
The progressive effect of disease severity on CMRglc in frontal, temporo-parieto-
occipital, motor, lentiform and cerebellar regions was demonstrated by post hoc 
comparisons between NL and PD patients at increasing H&Y stages. 
The proposal to explore brain metabolism in drug-naïve PD patients rose from 
the recent growing interest for imaging biomarkers, but also from the fact that 
[18F]FDG-PET studies supporting brain metabolism as a PD biomarker mainly ex-
amined already treated patients in the off-medication condition. The drawbacks of 
the washout designs were previously addressed for DAT-imaging studies, about 
which contrasting evidences concerning drug-induced striatal DAT regulation 
emerged (Guttman et al., 2001; Boij et al., 2008). Moreover, after antiparkinsonian 
therapies withdrawal the effect of medication on clinical symptoms persists for over 
two days, and therefore it could not be ruled out a possible persistent effect also on 
brain metabolic activity (Fahn et al., 2004). 
Our findings are consistent with previous [18F]FDG-PET studies, enrolling both 
drug-naïve and off-medication PD patients, which demonstrated in PD patients 
CMRglc reductions in frontal and temporo-parieto-occipital areas, and CMRglc in-
creases in subcortical regions and cerebellum (Asanuma et al., 2006; Ma et al., 2007; 
Juh et al., 2005; Hosokai et al., 2009). 
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So far, this [18F]FDG-PET study confirms in drug-naïve patients brain metabolic 
alterations in PD-related regions, therefore fulfilling a preliminary verification to the 
use of brain metabolism as a PD biomarker to monitor disease progression and 
treatment modulation effect. The brain metabolic changes found in drug-naïve PD 
patients motivate further research on the effect of therapeutic intervention on brain 
metabolism, in order to assess whether and in which PD-related regions pharmaco-
logical treatment could modify brain activity. 
2. Early functional changes related to dopamine depletion in drug naïve PD pa-
tients 
In studies 2 and 3 we explored the direct relation between the severity of striatal 
DA degeneration, brain metabolism, motor and cognitive impairment in early drug-
naïve PD patients in order to look for the early functional changes related to striatal 
DA depletion in PD. 
2.1 [123I]FP-CIT SPECT and clinical findings 
[123I]FP-CIT SPECT revealed, consistent with previous SPECT findings, lower 
NC DA impairment compared to the putamen, and a greater impairment in the puta-
men contralateral to the first and most affected body side compared to the ipsilateral 
one (Booij et al., 1997). DA depletion in contralateral NC was greater than in ipsila-
teral NC, although not reaching statistical significance. Contralateral NC BP were 
however strongly correlated with contralateral putaminal BP; this finding suggests 
that at early disease stages NC has already got involved in the disease process, as 
demonstrated by previous SPECT findings (Winogrodzka et al., 2003) and by PD an-
imal models (Pérez-Otaño et al., 1994), in which a parallel loss of DA terminals in 
putamen and NC was observed, although firstly and to a greater extent in the puta-
men. 
As concerns motor impairment, we recently demonstrated that [123I]FP-CIT 
SPECT BP measured with the LS method allows to find a correlation between puta-
minal DA impairment and clinical ratings of PD severity (Berti et al., 2008). On the 
other hand the LS method does not succeed in finding the correlation between DA 
impairment in the CN and early cognitive deficits in drug-naïve PD patients. 
In line with previous reports (Muslimović et al., 2005; Williams-Gray et al., 
2007), the present PD sample is characterized by cognitive deficits mainly in atten-
tion, executive and memory domains, nevertheless no significant correlation was 
found between NC BP and neuropsychological test scores. Our results are in disa-
greement with previous studies which found correlations between cognitive measures 
and striatal BP (Duchesne et al., 2002; Müller et al., 2000); however, they differ from 
the present one for several reasons. First of all some of them used a combined 
NC/putaminal BP (Duchesne, 2002). Further PD samples enrolled in these studies 
included patients already under antiparkinsonian treatment, at different disease stag-
es, and with a wider range of cognitive deficits. The aim of study 3 was to explore 
the early functional and cognitive changes related to the severity of DA depletion in 




macologically treated before. The contrasting evidences about the effect of DA re-
placement treatment on cognitive functions in PD given (Cools, 2006), this latter 
point became fundamental. The drawback of this accurate patients selection was that 
we reduced variability between patients, hence not ensuring enough variability for a 
correlation analysis between a biological parameter and cognitive variables. There-
fore the lack of a correlation between NC BP and cognitive dysfunction in our study 
may be due to the narrow range of neuropsychological test scores or, not less impor-
tant, to the small PD sample size, this latter point confirming the need for larger pa-
tients sample to obtain significant results relative to cognitive measure (Alexander et 
al., 2002). 
2.2 Brain metabolic changes related to DA degeneration in early PD 
In study 2 we found putaminal DA degeneration to be related to functional activ-
ity in premotor, dorsolateral prefrontal, anterior prefrontal, and orbitofrontal regions. 
The correlation between disease severity, as measured by putaminal BP, and 
rCMRglc in prefrontal cortical areas confirms the classical model of the basal ganglia 
circuit organization, derived from anatomical and electrophysiological studies in 
non-human primates (Albin et al., 1989, Obeso et al., 2000).  
The concept of frontostriatal loops has been widely used to explain the functional 
organization of frontostriatal circuits, by emphasizing the functional inter-
relationships between the neocortex and the striatum. According to this model, five 
parallel topographically organized functional circuits has been described: two motor 
circuits (i.e., the motor circuit & oculomotor circuit) and three complex (i.e., nonmo-
tor) circuits, originating from the dorsolateral prefrontal cortex (DLPFC), the anterior 
cingulate cortex (ACC), and the orbitofrontal cortex OFC (Alexander et al., 1986). 
In study 2 we found a positive correlation between putaminal BP and rCMRglc 
not only in frontal regions belonging to the motor loop, but also in dorsolateral, ante-
rior prefrontal and orbitofrontal regions, which are part of the associative and limbic 
loop (Alexander, 1986). Indeed, the loss of dopaminergic projections in PD is not 
confined to the putamen but at the same time occurs also in the caudate nucleus and 
in ventral striatum, which are the striatal relais of associative and limbic frontostriatal 
loops, therefore connected with DLPFC, APFC and OFC. 
This finding led us to further investigate the direct relation between DA degen-
eration in the NC and brain metabolism. As expected we found caudate DA depletion 
to be related to functional changes in brain regions belonging to associative and lim-
bic frontostriatal circuits, i.e. DLPFC, OFC and ACC. Therefore, besides motor cir-
cuits, we further confirm the partially anatomical and functional segregation of non 
motor frontostriatal circuits too. Recent MRI tractography studies, by exploring NC 
connections in vivo, in humans, showed that the head of NC was connected to me-
dial, ventral and dorsolateral prefrontal cortex, prefrontal pole, and supplementary 
motor area (Lehericy et al., 2004).  
The essential pathophysiological characteristic of the PD state is increased neu-
ronal firing activity in the output nuclei of the basal ganglia leading to excessive in-
hibition of thalamocortical motor system. The correlation between the severity of DA 
degeneration in the putamen and brain metabolic alteration in several prefrontal areas 
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therefore confirm pathopshysiological changes occurring in the functional organiza-
tion of the basal ganglia in PD. Indeed, the excessive inhibition of thalamocortical 
projections may be at the basis of reduced prefrontal rCMRglc correlating with re-
duced BP. Whether thalamocortical inhibition extends to different cortico-striatal 
pallidal loops is not yet known, since most studies in PD and animal models have fo-
cused on the motor features associated with DA depletion and replacement, and have 
not addressed the molecular and physiological changes that occur in the different 
basal ganglia subcircuits (Obeso et al., 2008). The finding of a correlation between 
NC DA depletion and dorsolateral, orbitofronatal, anterior cingulate activity how-
ever, suggest that reduced prefrontal rCMRglc correlating with reduced NC BP may 
be due to the excessive inhibition of thalamocortical projections in associative and 
limbic regions. 
Besides DLPFC, OFC and ACC regions which are directly involved in classical 
frontostriatal circuits, we found a positive correlation between NC DA depletion and 
rCMRglc reduction in superior and middle temporal regions, and specifically in the 
temporal pole (TP). In support of a direct connection between temporal lobe and NC, 
the temporal lobe has been demonstrated to be a target of basal ganglia outputs in 
functional connectivity studies (Postuma and Dagher, 2006), in anatomical studies in 
animals (Middleton and Strick, 1996), and in recent MRI tractography study (Leh et 
al., 2007). In turn, the TP, thanks to its anatomical position, is highly interconnected 
with OFC and with the amygdala (Olson, 2007), and anatomical and functional con-
nections between ventral striatum and the basolateral amygdala have been reported 
(Cardinal et al., 2002; Postuma and Dagher., 2006). 
The correlation between 123I-FP-CIT putaminal binding potential and rCMRglc, 
demonstrates a direct association between a biomarker of dopaminergic degeneration 
severity and cortical metabolic reduction in several frontal and prefrontal areas, such 
as PMC, DLPFC, APFC and OFC. Our findings, hence, turn the attention on [18F]-
FDG uptake in prefrontal regions as a potential biomarker in PD. A biomarker is a 
characteristic that is objectively measured and evaluated as an indicator of normal or 
pathogenic biological processes (Biomarkers Definition Working Group, 2001). Ac-
cording with that, prefrontal [18F]-FDG uptake might fulfil the basic requirements 
for a biomarker, since it can be objectively measured and it is associated with the PD 
pathogenic process, i.e. the dopaminergic degeneration as demonstrated in study 2. 
On the other hand the correlation between NC DA impairment and reduced 
rCMRglc in associative and limbic regions (study 3) gives further evidences of an 
early involvement of non motor circuit in PD. More interestingly, the metabolic re-
duction in temporolimbic regions was uniquely related to DA depletion in NC. The 
early involvement of temporolimbic regions in PD disease progression has been 
demonstrated by neuropathological studies (Braak et al., 2003), which proposed the 
temporolimbic pathology to parallel occur to the degeneration of nigrostriatal DA 
neurons. Our finding of a selective correlation between NC DA degeneration and 
temporolimbic hypometabolism might suggest additional early functional changes in 
temporolimbic regions more directly mediated by NC DA depletion. 
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